Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Replimune Group, Inc. (REPL) Financial Statements

Free cash flow over the same period: -$280.5M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

REPLReplimune Group, Inc.Follow REPL — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
1.1B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
4 Nov, in 11 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2020
Mar 20
FY2021
Mar 21
FY2022
Mar 22
FY2023
Mar 23
FY2024
Mar 24
FY2025
Mar 25
FY2026
Mar 26
TTM
Jun 26
Trend
Research & development38.856.879.5126.5175.0189.4221.2212.6
Operating income-56.2-80.0-118.3-177.1-234.8-261.6-319.9-297.7
Pre-tax income-52.6-80.9-118.0-174.0-215.4-246.8-314.5—
Income tax0.00.00.00.30.40.5-0.6—
Net income-52.6-80.9-118.0-174.3-215.8-247.3-313.9-297.0
Diluted EPS ($)-1.54-1.75-2.26-2.99-3.24-3.07-3.38-3.15
Diluted shares (mn)——52.258.266.680.692.8—

USD millions · SEC XBRL

Replimune Group, Inc. — questions

What is Replimune Group, Inc.'s net income?
-$297.0M over the twelve months to 2026-06-30.
What is Replimune Group, Inc.'s free cash flow?
-$280.5M over the twelve months to 2026-06-30.
What are Replimune Group, Inc.'s diluted earnings per share?
$-3.15 over the twelve months to 2026-06-30.

Every figure on this page comes from Replimune Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.